Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study.
- DOI
- 10.1016/j.jtocrr.2026.101064
- Published
- 2026 Nov
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2026.101064,
title = {Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study.},
author = {Kim J and Park S and Lee GW and Kim IH and Kim DW and Lee YG and Cho JH and Cho EK and Lee HW and Park JH and Kang EJ and Lee Y and Son NH and Gwon SH and Jung HA and Sun JM and Lee SH and Ahn JS and Ahn MJ},
year = {2026},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2026.101064},
url = {https://doi.org/10.1016/j.jtocrr.2026.101064}
}RIS
TY - JOUR TI - Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study. AU - Kim J AU - Park S AU - Lee GW AU - Kim IH AU - Kim DW AU - Lee YG AU - Cho JH AU - Cho EK AU - Lee HW AU - Park JH AU - Kang EJ AU - Lee Y AU - Son NH AU - Gwon SH AU - Jung HA AU - Sun JM AU - Lee SH AU - Ahn JS AU - Ahn MJ PY - 2026 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2026.101064 UR - https://doi.org/10.1016/j.jtocrr.2026.101064 ER -
APA
J, K., S, P., GW, L., IH, K., DW, K., YG, L., JH, C., EK, C., HW, L., JH, P., EJ, K., Y, L., NH, S., SH, G., HA, J., JM, S., SH, L., JS, A., & MJ, A. (2026). Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2026.101064
Source records
- pubmed · retrieved 2026-11-10T16:52:18.695Z